Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > gemcitabine (Gemzar))

Gemcitabine (Gemzar) : Lilly : Nucleoside analogue

Gemcitabine (Gemzar) Clinical Research
Gemcitabine (Gemzar) Side Effects
Gemcitabine (Gemzar) and Carboplatin (Paraplatin)
Gemcitabine (Gemzar) and Vinorelbine (Navelbine)
Gemcitabine (Gemzar) and Alimta (pemetrexed)
Gemcitabine (Gemzar) for SCLC

Clinical Research

Use of Gemcitabine in Non-Small Lung Cancer (Cancer Care Ontario Practice Guideline Initiative)
Clinical practice guideline for the use of gemcitabine in non-small cell lung cancer. Available as recommendations, structured abstract or full text. Intended for physicians. [9/02]

Gemzar (Lilly)
Manufacturer's website offers basic information about Gemzar.

Gemcitabine (Gemzar) - Recent MEDLINE Abstracts (PubMed)

Gemcitabine (Gemzar) - Clinical Trials (ClinicalTrials.gov)

Side Effects

Gemzar Therapy Side Effects (Eli Lilly)
Describes possible side effects that may be experienced with Gemzar (gemcitabine) therapy.

Radiation Recall Reaction Following Gemcitabine (PubMed)
Abstract from a case report in the August-September 2001 issue of Lung Cancer describing a case of dermatitis and myositis in the upper thorax after administration of gemcitabine. Thought to be a case of radiation recall phenomenon, cessation of gemcitabine and and systemic steroids are recommended for management and symptomatic relief. [9/01]

Gemcitabine (Gemzar) and Carboplatin (Paraplatin)

Gemcitabine (Gemzar) and Carboplatin (Paraplatin) - Recent MEDLINE Abstracts (PubMed)

Gemcitabine (Gemzar) and Vinorelbine (Navelbine)

The Novel and Effective Nonplatinum, Nontaxane Combination of Gemcitabine and Vinorelbine in Advanced NSCLC (Cancer)
Reports on a Phase II study published in the July 2002 issue of Cancer that evaluated the efficacy of gemcitabine and vinorelbine in both untreated and previously treated patients with stage IIIB (with pleural effusion) or stage IV NSCLC. Concluded that gemcitabine/vinorelbine is an active, well-tolerated combination in both front-line and second/third line therapy for stage IIIB/IV NSCLC. The response rate, median survival rate, and one year survival compare favorably with platinum-based regimens. The toxicity profile of the gemcitabine/vinorelbine combination is favorable with minimal side effects aside from granulocytopenia. [5/02]

Gemcitabine (Gemzar) and Vinorelbine (Navelbine) - Recent MEDLINE Abstracts (PubMed)

Gemcitabine (Gemzar) and Alimta (pemetrexed)

Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced NSCLC (PubMed)
Study, published in the August 15, 2004 issue of Clinical Cancer Research, that evaluated the efficacy and toxicity of pemetrexed (Alimta) and gemcitabine (Gemzar) in patients with advanced NSCLC. Results of the study indicated this combination had good tolerance and achieved promising overall survival with extended one- and two-year survival rates. Recommends further evaluation in randomized trials. [8/04]

Gemcitabine (Gemzar) for SCLC

Single-agent Gemcitabine in Patients with Resistant SCLC (Annals of Oncology)
Abstract of a study published in the April 2001 issue of the Annals of Oncology to assess the activity and toxicity of gemcitabine in patients with resistant SCLC. Concludes that gemcitabine has modest activity in patients with resistant SCLC. [4/01]


 

Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 26-Apr-2011
Karen Parles, MLS Editor